P09874 (PARP1_HUMAN) Homo sapiens (Human)

Poly [ADP-ribose] polymerase 1 UniProtKBInterProSTRINGInteractive Modelling

1014 aa; Sequence (Fasta)

Available Structures

95 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
Human PARP1 deltaV687-E688 bound to UKTT5 (compound 10) and to a DNA double strand break. Heteromer
3-1014
100.0YH0;ZN;
Human PARP1 deltaV687-E688 bound to NAD+ analog EB-47 and to a DNA double strand break. Heteromer
6-1014
100.0EDO;UHB;ZN;
Human PARP1 deltaV687-E688 bound to a DNA double strand break. Heteromer
6-1014
100.0EDO;ZN;
Structure of Human PARP-1 bound to a DNA double strand break Heteromer
6-1011
100ZN;EDO;
Structure of Human PARP-1 bound to a DNA double strand break in complex with (2R)-5-fluoro-2-methyl… Heteromer
6-1011
100.0ZN;2UR;
Structure of Human PARP-1 bound to a DNA double strand break in complex with (2Z)-2-{4-[2-(morpholi… Heteromer
6-1011
100.0ZN;2UT;
Structure of Human PARP-1 bound to a DNA double strand break in complex with (2Z)-2-(2,4-dihydroxyb… Heteromer
6-1011
100.0ZN;2US;
Structure of human PARP1 domains (Zn1, Zn3, WGR and HD) bound to a DNA double strand break. Heteromer
5-776
100.0ZN;
Structure of human PARP1 domains (Zn1, Zn3, WGR, HD) bound to a DNA double strand break. Heteromer
5-776
100.0ZN;
The complex structure of Timeless_PAB and PARP-1_catalytic domain Heteromer
Q9UNS1;
665-1009
100.0GOL;ACT;
Crystal structure of HPF1/PARP1 complex Heteromer
Q9NWY4;
788-1014
100.0UNU;
Crystal structure of the human PARP-1 DNA binding domain in complex with DNA Heteromer
6-202
100ZN;
Nuc147 bound to multiple BRCTs Heteromer
P04908; P06899; P62805; P68431;
387-482
100
Nuc147 bound to single BRCT Heteromer
P04908; P06899; P62805; P68431;
387-482
100
PARP complexed with A861695homo-6-mer662-1011
99.7178P;
Crystal structure of catalytic domain of human poly(ADP-ribose) polymerase complexed with a quinoxa…homo-4-mer662-1011
100CNQ;
Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitorhomo-2-mer662-1014
100.0SO4;GOL;FSU;
Crystal structure-based design and disovery of a novel PARP1 antiagonist (BL-PA10) that induces apo…homo-2-mer662-1011
100GOL;SO4;TP0;
Crystal Structure of the Third Zinc-binding domain of human PARP-1homo-2-mer225-359
100ZN;EOH;GOL;
Human PARP-1 zinc finger 1 (Zn1) bound to DNAhomo-2-mer5-91
100ZN;
Human PARP-1 zinc finger 1 (Zn1) bound to DNAhomo-2-mer5-91
100ZN;
Crystal structure of the catalytic domain of human PARP1 in complex with veliparibmonomer662-1011
99.7178P;SO4;
Structure of the catalytic domain of PARP1monomer662-1011
100SO4;
Crystal structure of the catalytic domain of human PARP1 (apo)monomer662-1011
99.71SO4;DMS;
PARP1 catalytic domain in complex with a selective pyridine carboxamide-based inhibitor (compound 2…monomer662-1011
99.71VKQ;SO4;
Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitormonomer662-1011
99.717U9;
PARP1 catalytic domain in complex with isoquinolone-based inhibitor (compound 16)monomer662-1011
99.71VKT;SO4;
PARP1 catalytic domain in complex with 8-chloroquinazolinone-based inhibitor (compound 9)monomer662-1011
99.71VKW;SO4;
Structure of the catalytic domain of PARP1 in complex with veliparibmonomer662-1011
10078P;SO4;
ADP-ribosyltransferase 1 (PARP1) catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.711WI;SO4;
Crystal Structure of human PARP-1 CAT domain bound to inhibitor rucaparibmonomer662-1011
99.71RPB;GOL;SO4;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.717UL;
Structure of human PARP1 catalytic domain bound to a phthalazinone inhibitormonomer662-1011
99.717U3;
PARP complexed with benzo[1,4]oxazin-3-one inhibitormonomer662-1011
99.711WQ;
Crystal structure of the catalytic domain of human PARP1 in complex with olaparibmonomer662-1011
99.7109L;SO4;
Human PARP1 (ARTD1) - Catalytic domain in complex with inhibitor ME0527monomer662-1011
99.71EZ2;SO4;
PARP complexed with A968427monomer662-1011
99.71GJW;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.716WX;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.714YR;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.716WZ;
Crystal structure of PARP catalytic domain in complex with novel inhibitorsmonomer662-1011
99.7115R;
PARP complexed with A906894monomer662-1011
99.71L3L;
PARP complexed with A861696monomer662-1011
99.713GN;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.716X2;
Structure of human PARP1 catalytic domain bound to a benzoimidazole inhibitormonomer662-1011
99.717U6;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.716WY;
Structure of human PARP1 catalytic domain bound to a quinazoline-2,4(1H,3H)-dione inhibitormonomer662-1011
99.717TX;
Complex structure of PARP1 catalytic domain with pamiparibmonomer662-1011
99.71DS9;GOL;
Crystal structure of PARP catalytic domain in complex with novel inhibitorsmonomer662-1011
99.7115S;
Crystal structure of the catalytic domain of human PARP1 in complex with inhibitor EB-47monomer662-1011
99.71UHB;SO4;
PARP complexed with A620223monomer662-1011
100AAI;
Human ADP-ribosyltransferase 1 (PARP1) catalytic domain bound to a pyrazolopyrimidine carboxamide i…monomer662-1011
99.71ERV;SO4;
Human artd1 (parp1) - catalytic domain in complex with inhibitor xav939monomer662-1011
99.71SO4;XAV;
Human ADP-ribosyltransferase 1 (PARP1) catalytic domain bound to Fluzoparib (SHR3162)monomer662-1011
99.7125I;SO4;
Crystal structure of catalytic domain of human poly(ADP-ribose) polymerase with a novel inhibitormonomer662-1011
100FRM;
Crystal structure of human poly(ADP-ribose) polymerase complexed with a potent inhibitormonomer662-1011
100FRQ;
Structure of the catalytic domain of PARP1 in complex with niraparibmonomer662-1010
100.03JD;SO4;
Structure of the catalytic domain of PARP1 in complex with olaparibmonomer662-1010
100.009L;
Catalytic domain of human PARP-1 in complex with the inhibitor MC2050monomer663-1011
100.0NI;EDO;O3H;
Structure of the catalytic domain of PARP1 in complex with talazoparibmonomer662-1010
100.02YQ;
Human artd1 (parp1) - catalytic domain in complex with inhibitor niraparibmonomer662-1010
99.713JD;SO4;GOL;
HUMAN ARTD1 (PARP1) - CATALYTIC DOMAIN IN COMPLEX WITH INHIBITOR TALAZOPARIBmonomer662-1010
99.712YQ;
novel orally efficacious inhibitors complexed with PARP1monomer662-1010
99.718E6;SO4;
novel orally efficacious inhibitors complexed with PARP1monomer662-1010
99.718EC;SO4;
Structure of PARP1 catalytic domain bound to inhibitor BMN 673monomer662-1010
100.0SO4;2YQ;GOL;
novel orally efficacious inhibitors complexed with PARP1monomer662-1010
99.71SO4;8E3;
Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitormonomer662-1010
100.0D7N;SO4;
Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparibmonomer662-1010
99.71SO4;RPB;
Human ARTD1 (PARP1) - Catalytic domain in complex with inhibitor PJ34monomer662-1010
99.69P34;SO4;
PARP complexed with A927929monomer663-1010
99.71A92;
Crystal Structure of human PARP-1 CAT domain bound to inhibitor UKTT15monomer664-1011
99.71L1S;SO4;
Human ARTD1 (PARP1) - Catalytic domain in complex with inhibitor ME0328monomer663-1010
99.71MEW;
Crystal Structure of human PARP-1 CAT domain bound to inhibitor EB-47monomer664-1011
99.71UHB;SO4;
Crystal Structure of human PARP-1 ART domain bound inhibitor UTT63monomer788-1010
100KYP;SO4;DMS;
Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT93monomer788-1010
100KYJ;SO4;DMS;
Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT57monomer788-1010
100KYY;SO4;DMS;
Crystal Structure of human PARP-1 ART domain bound to inhibitor UKTT-15monomer788-1010
100GLC;DMS;1PE;L1S;SO4;
Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT103monomer788-1010
100CIT;DMS;KYV;CL;
Crystal Structure of human PARP-1 ART domain bound to inhibitor UTT83monomer788-1010
100KYM;CIT;DMS;CL;
Crystal structure of constitutively active PARP-1monomer788-1010
100.01PE;09L;SO4;
Crystal structure of human PARP1 ART domain bound to inhibitor UKTT5 (compound 10)monomer788-1010
100GLC;YH0;DMS;PEG;
Human PARP-1 bound to NAD+ analog benzamide adenine dinucleotide (BAD)monomer789-1010
100DQV;
The crystal structure of a helical domain deleted PARP1 in complex with isoindolinone based inhibit…monomer788-1009
99.54VHU;
Crystal structure of human PARP1 ART domain bound to inhibitor UKTT22 (compound 14)monomer789-1009
100GLC;CIT;DMS;YVB;EDO;
Crystal structure of human PARP1 ART domain bound to inhibitor UKTT10 (compound 13)monomer789-1009
100DMS;CIT;YNQ;
1H, 13C and 15N chemical shift assignments and solution structure for PARP-1 F1F2 domains in comple…monomer1-214
100ZN;
Solution structure of WGR domain of poly(ADP-ribose) polymerase-1monomer518-643
100
Domain C of human PARP-1monomer233-358
100ZN;
Solution structure of the second Zn-finger domain of poly(ADP-ribose) polymerase-1monomer103-223
100ZN;
Human PARP-1 zinc finger 2monomer103-214
100ZN;
Human PARP-1 zinc finger 1monomer1-108
100ZN;
Solution structure of BRCT domain of poly(ADP-ribose) polymerase-1monomer387-486
99.0
Human PARP-1 zinc finger 2 (Zn2) bound to DNAmonomer109-201
100ZN;
Solution structure of the first zf-PARP domain of human Poly(ADP-ribose)polymerase-1monomer1-93
100ZN;
Human PARP-1 zinc finger 2 (Zn2) bound to DNAmonomer110-200
100ZN;

6 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
7s6h.1.Amonomer0.80531-1014
UHB;99.59
2cok.1.Amonomer0.76387-485
98.99
2n8a.1.Amonomer0.691-214
ZN;100.00
2riq.1.Bmonomer0.69225-357
ZN;100.00
7s68.1.Dmonomer0.66109-357
ZN;74.39
7s6m.1.Bmonomer0.566-359
DC;ZN;94.86